News

Impact of erdostein on bacterial biofilm −⁠ and what it means for clinical practice?

28. 11. 2023 Source: Cough Therapy

One of the substances that could potentially influence the success of treatments for infections associated with biofilm formation in the future is erdostein. This medication is used in the treatment of both acute and chronic diseases of the respiratory system (including chronic obstructive pulmonary disease) usually accompanied by increased mucus production. Its effect is mediated by several mechanisms that can also affect bacterial biofilm.

Low Molecular Weight Heparin in an ECMO Patient −⁠ Case Study

Extracorporeal membrane oxygenation (ECMO) has an irreplaceable role in intensive care medicine. In the context of preventing complications caused by blood clot formation, unfractionated heparin is…

28. 11. 2023 Source: Thromboprophylaxis

Use of Enoxaparin in Patients After Implantation of Left Ventricular Assist Device

Left ventricular assist devices (LVAD) are utilized in patients with end-stage heart failure (HF). Warfarin is typically employed for long-term anticoagulation, but there are no standardized…

28. 11. 2023 Source: Thromboprophylaxis

Prophylaxis with Enoxaparin After Total Knee or Hip Replacement

Venous thromboembolic disease is a significant cause of complications in surgical patients during and after hospitalization. The authors of a recently published Portuguese observational study…

28. 11. 2023 Source: Thromboprophylaxis

What Are the Impacts of Not Administering Extended VTE Prophylaxis in Oncology Patients After GIT Surgeries?

In a freshly published retrospective study, experts from the University of Arkansas investigated how well the professional recommendation that cancer patients undergo extended venous thromboembolism…

28. 11. 2023 Source: Thromboprophylaxis

FEIBA in Real Clinical Practice –⁠ Fresh Data from the Observational Study FEIBA GO

FEIBA GO (Global Outcome) was a prospective observational study evaluating the long-term administration of FEIBA, its safety, efficacy, and quality of life for patients with hemophilia A or B and…

27. 11. 2023 Source: Hemophilia

Untreated Bleeding in Hemophilia A –⁠ An Underestimated Problem? To What Extent?

How common is bleeding in hemophilia A that ultimately goes untreated? This was the focus of a recent study, the results of which were published in the journal Research and Practice in Thrombosis and…

27. 11. 2023 Source: Hemophilia

Economic Costs and Concomitant FVIII Consumption in Hemophilia Patients Treated with Emicizumab in the 1st Year −⁠ A US Experience

The authors of a recent study, summarizing real-world experience from the US, focused on the concomitant consumption of FVIII (Factor VIII) concentrates during emicizumab prophylaxis and the…

27. 11. 2023 Source: Hemophilia

Minimally Invasive Treatment of Pilonidal Sinus: Laser and Negative Pressure Therapy as a Gentle and Effective Modality

The increasing incidence of pilonidal sinus contributes to the development of new treatment methods. Experiences from AGEL Hospital Přerov show that the methods SiLaC (sinus laser ablation of the…

24. 11. 2023 Source: Wound Healing

Reduction of Enthesitis in Patients with Psoriatic Arthritis Taking Tofacitinib

Inflammation in the area where a tendon, ligament, or joint capsule attaches to the bone occurs in 35–50% of patients with psoriatic arthritis (PsA). Its presence is associated with higher activity…

24. 11. 2023 Source: Arthritis

How do body weight and metabolic parameters change in patients first hospitalized for psychosis?

The most common cause of death in patients with schizophrenia is cardiovascular disease, which is closely related to obesity or metabolic syndrome. The study presented below examined changes in body…

24. 11. 2023 Source: Modern Treatment of Schizophrenia

Prof. Hana Rosolová: According to recent studies, caution is needed with beta-blockers only in severe cases of asthma and COPD

Beta-blockers (BB) are among the most widely used drug groups in cardiology. While their position is clear in some indications, it is debated in others. Additionally, individual BBs differ in various…

23. 11. 2023 Source: Cardiovascular Continuum

Reduction of Inflammation in Vertebral Bodies and Posterolateral Structures of the Spine in Patients with Ankylosing Spondylitis Treated with Tofacitinib

A post hoc analysis of a phase II study with tofacitinib in patients with active ankylosing spondylitis (AS) evaluated the suppression of spinal inflammation using magnetic resonance imaging (MRI)…

23. 11. 2023 Source: Arthritis

How Do Patients Themselves Perceive Today's Treatment Options for ITP and What Are Their Biggest Fears?

What is the perception and view of the treatment options for immune thrombocytopenia (ITP) from the patients' perspective, what do they fear, what approaches do they prefer, and why? Lozano et al.…

21. 11. 2023 Source: Immune Thrombocytopenia

Romiplostim brings benefit also to patients with ITP lasting less than 1 year

What is the role of second-line therapy, in this case romiplostim, in the management of adult ITP patients who have not yet reached the chronic phase of the disease?

21. 11. 2023 Source: Immune Thrombocytopenia

1 … 18 19 20 21 22 … 115

Back Filter by speciality

Remove filters

Popular this week